Another of PepGen’s trials has encountered resistance from the FDA, with the regulator now putting the company’s plans to ...

After its eye disease antibody flopped in an FDA-requested clinical trial in late November, Outlook Therapeutics is ...

Discover how the Inventus Connect eSIM solutions, designed specifically for provisioned devices in clinical trials, are ...

Foghorn Therapeutics has finally given up on its only wholly-owned clinical-stage candidate after the troubled cancer drug ...

Edgewise Therapeutics’ lead candidate has been shown to reduce levels of a biomarker related to skeletal muscle damage in a ...

PureTech’s only internal drug program has slowed lung function decline in a phase 2 trial in idiopathic pulmonary fibrosis ...

Pharming is paying $66.1 million to acquire Swedish biotech Abliva and its phase 2-stage med that the Dutch drugmaker ...

Incyte is dropping a program for patients with myelofibrosis-related anemia after its investigational small molecule failed ...

Medtronic reported that a patient has completed the first procedure with the latest version of its ingestible camera, used to ...

AbbVie is paying $200 million to snap up Nimble Therapeutics, a Roche spinout working to develop oral peptide treatments in the autoimmune space. | AbbVie is paying $200 million to snap up Nimble ...

BeiGene has struck a $150 million deal to license a cancer candidate from CSPC Zhongqi Pharmaceutical Technology, positioning ...

Newron Pharmaceuticals has secured 44 million euros ($46.1 million) in upfront cash from an Eisai subsidiary for select Asia ...